If you’ve spent a lot of time outdoors in New England, you’ve likely crossed paths with, and probably stepped on, lichens.

Lipella Pharmaceuticals (LIPO) announced that its abstract on LP-10 for the treatment of Oral Lichen Planus, OLP, has been accepted for podium ...

Lipella Pharmaceuticals Abstract on Oral Lichen Planus Treatment Accepted for Podium Presentation at 2025 AAOM/EAOM International Meeting Conference on “Global Transformation in Oral Medicine” ...

The post Lipella Reports Additional Positive Data from Phase 2a Trial of LP-310 in Oral Lichen Planus appeared first on PRISM MarketView.

Statistically significant improvements observed across clinical endpoints; final cohort results expected in Q2 2025 ...

Lipella Pharmaceuticals (LIPO) announced topline results from the second cohort of its Phase 2a multicenter, dose-ranging trial evaluating ...

Second Cohort Results Highlight Efficacy Across All Key Measures and Reinforce Safety of Twice-Daily Oral Rinse Phase 2a Study Now Fully Enrolled Across All Three Dose Cohorts Advancing Toward Phase ...